I am starting to now believe - rather than hope, that all 4 of the current phase 2 trials will be successful.
Similar ailments treated by the same drug.
Efficacy is the only real variant.
And then phase 3 - with this science? With this management team - I believe they will be successul too (albeit with the fact that Neuren themselves have not as yet got a drug past phase 3).
They must have learnt something with Trofinetide regarding that! And they have plenty of cash to hire/contract the right people to do the job.
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.78 |
Change
0.230(1.31%) |
Mkt cap ! $2.240B | |||
| Open | High | Low | Value | Volume |
| $17.83 | $17.99 | $17.35 | $16.12M | 911.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11000 | $17.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.80 | 10070 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |